Tagolimumab
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Tagolimumab, covering 2025-12-02 to 2025-12-02. Get the full timeline:
Most recent: Clinical Trial Update: Lucentis Plus Tagolimumab in PD-L1+, HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitors [Phase 2]